1-Phenyl-1-<2-carboxyaethyl>-harnstoff | 24371-62-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Phenyl-1-<2-carboxyaethyl>-harnstoff
• 英文别名: 3-(1-Phenyl-ureido)-propionic acid；3-(N-carbamoylanilino)propanoic acid
• CAS: 24371-62-8
• 化学式: C₁₀H₁₂N₂O₃
• 分子量: 208.217
• InChiKey: FFQLMOLDTSZBCK-UHFFFAOYSA-N

物化性质

• 沸点：
  412.1±47.0 °C(Predicted)
• 密度：
  1.335±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  2,3-二氯-1,4-萘醌 、 1-Phenyl-1-<2-carboxyaethyl>-harnstoff 以 水 为溶剂， 反应 14.0h， 以36%的产率得到2-(phenylamino)naphtho[2,3-d]oxazole-4,9-dione
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Novel N-Carboxyalkyl-N-phenyl-2-aminothia(oxa)zole Derivatives

  摘要：

  N-Phenyl-N-thiocarbamoyl-alpha- and beta-methyl-beta-alanines were converted into a series of 1,3-thiazole derivatives by treatment with chloroacetaldehyde and haloketones. The reaction of N-phenyl-N-thiocarbamoyl-beta-alanines and N-carbamoyl-N-phenyl-beta-alanines with 2,3-dichloro-1,4-naphthoquinone and 2,3-dichloroquinoxaline provided naphthoquinone- and quinoxaline-fused thiazoles and oxazoles, respectively. A number of the synthesized compounds exhibited good antibacterial activity against Staphylococcus aureus and Salmonella enteritidis with MIC and MBC values (62.5 and 125 mu g/mL, respectively) which are the same or even lower than those for the antibiotic oxytetracycline.

  DOI：

  10.3987/com-15-13181

文献信息

• Compositions and methods for the treatment of aberrant angiogenesis
  申请人：The Schepens Eye Research Institute, Inc.

  公开号：US11229662B2

  公开（公告）日：2022-01-25

  The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.

  本主题提供了用于抑制、治疗或预防受试者异常血管生成的组合物、制剂和方法。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS
  申请人：The Schepens Eye Research Institute, Inc.

  公开号：US20190350961A1

  公开（公告）日：2019-11-21

  The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.
• NANO-EMULSION OF CBFß-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERY
  申请人：The Schepens Eye Research Institute, Inc.

  公开号：US20200375899A1

  公开（公告）日：2020-12-03

  The invention provides ocular formulations and features a nano-emulsion composition, e.g., a nano-emulsion comprising a CBFβ-RUNX1 inhibitor. The composition comprises a particle with a length of less than 200 nanometers in at least one dimension.
• RUNX1 INHIBITION FOR TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND CONDITIONS ASSOCIATED WITH EPITHELIAL TO MESENCHYMAL TRANSITION
  申请人：The Schepens Eye Research Institute, Inc.

  公开号：US20200377888A1

  公开（公告）日：2020-12-03

  The present subject matter provides compositions, formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE L'ANGIOGENÈSE ABERRANTE
  申请人：SCHEPENS EYE RES INST

  公开号：WO2018093797A1

  公开（公告）日：2018-05-24

  The present subject matter provides compositions, formulations, and methods for inhibiting, treating, or preventing aberrant angiogenesis in a subject.